To pioneer transformative minimally invasive ophthalmic fluid delivery devices that safely help preserve and restore vision and improve the quality of life for patients, beginning with the treatment of retinal detachment and expanding to a broader range of ophthalmic disorders.
To be the global leader in pioneering treatment options for various ocular disorders by advancing innovative interventions that improve access to suprachoroidal and subretinal locations.
Any securities that may be sold will be sold subject to the terms and conditions of a definitive sales document provided in connection with the offering of the securities and that no other written or oral statement by or on behalf of the company will be deemed to be a representation, warranty or covenant of Dragonfleye Therapeutics Corp. (the “Company”);• This investor presentation is confidential and that by attending the presentation, the prospective investor agrees not to transmit, reproduce or make the presentation available to anyone without the written consent of the Company;• This investor presentation does not constitute investment advice and that prospective investors should thoroughly review any sales documents and should consult with their own legal, regulatory, tax, business, investment, financial, accounting or other advisors, as needed to make their own decision to purchase securities of the company.• There are risks associated with any investment in securities of the Company and that a return is not guaranteed;• Any securities will only be offered in jurisdictions where they may be lawfully offered by the Company, and all subscribers must be residents of Canada;• No securities regulatory authority has expressed an opinion about the merits of the securities of the Company;• The information provided is of a certain date and that the company is not obligated to update or revise such information to reflect new events or circumstances.